The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Sarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two ...

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...